Recession Proof Stocks to Own Right Now

There is also a pure play stock to consider. Glucose Health, Inc. (OTC Pink: GLUC).

49

Motley fool recently ran an article titled “3 High-Growth Stocks to Buy During a Stock Market Crash”.

The article discusses how being an investor during the Covid-19 era has not been easy.  The uncertainty has thrown stocks to all-time lows, bankrupted some, forced consolidation of others and yet, some have also reached dizzying new highs.  

Where do you go for safety should be a relapse? One answer is clearly Amazon (NASDAQ: AMZN).  People will still need to shop, and shop with the least personal contact as possible.  Amazon is up about 33% since its pre-Covid-19 highs.  

Lastly the article references cybersecurity companies as a “basic need” along with healthcare.  Okta (NASDAQ: OKTA) is pushing 30% past its pre-Covid-19 high.  Health care stocks are certainly among the smartest places to park funds during turbulent times.  Take Intuitive Surgical (NASDAQ: ISRG).  This stock continues to beat its pre-Covid-19 highs. 

One niche in the health care space is the diabetic/adult nutrition & medical foods sector.  Diabetes has long been classified as a national epidemic by the Centers for Disease Control.  This sector is dominated by giants like Nestle (OTC: NSRGY) and Abbott Labs (NYSE: ABT).

But…there is also a pure play stock to consider.  Glucose Health, Inc. (OTC Pink: GLUC).  The Company manufacturers nutritional beverages for the diabetic-adult nutrition category under the registered trademark GLUCODOWN®. 

GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and digestive health

GLUCODOWN® has made its way onto the shelves of the nation’s biggest pharmacy chains, right alongside the diabetic nutrition products from Nestle and Abbott, as well as online at Amazon.com (NASDAQ: AMZN) – yet the Company, Glucose Health, Inc. is still trading below a $20 million valuation!

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

What are the revenues of this company going to look like when the latest GLUCODOWN® sales numbers are reported for Q3 and Q4? 

Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list. 

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated four thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here https://emerginggrowth.com/4582-6827465/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments